RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.840
-0.030 (-3.46%)
At close: Apr 28, 2026, 4:00 PM EDT
0.845
+0.005 (0.60%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
RenovoRx, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Shaun Bagai |
Contact Details
Address: 2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States | |
| Phone | 650 284 4433 |
| Website | renovorx.com |
Stock Details
| Ticker Symbol | RNXT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001574094 |
| CUSIP Number | 75989R107 |
| ISIN Number | US75989R1077 |
| Employer ID | 27-1448452 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaun R. Bagai | Chief Executive Officer, Secretary and Director |
| Dr. Ramtin Agah M.D. | Founder, Executive Chairman and Chief Medical Officer |
| Leesa Gentry | Chief Clinical Officer |
| Mark Voll | Chief Financial Officer and Principal Accounting Officer |
| Robert Strasser | Vice President of Operations and Research & Development |
| Ryan Witt | Senior Vice President and Head of Corporate Strategy and Partnerships |
| Ronald B. Kocak CPA, CGMA | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | EFFECT | Notice of Effectiveness |
| Apr 27, 2026 | 424B3 | Prospectus |
| Apr 27, 2026 | SCHEDULE 13G/A | Filing |
| Apr 16, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 9, 2026 | D | Notice of Exempt Offering of Securities |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 8-K | Current Report |